“Bimekizumab versus Ustekinumab Efficacy Across Subgroups of Patients with Moderate to Severe Plaque Psoriasis: Results from the Multicenter, Randomized, Double-Blinded Phase 3 BE VIVID Trial” (2021) SKIN The Journal of Cutaneous Medicine, 5(1), p. s16. doi:10.25251/skin.5.supp.16.